RT @tgtxdough: @tgtxdough LR NEURO accompanies approaching LIFE CYCLE inflection points -M&A $ACAD $NBIX $SAGE $GWPH $ALDR https://t.co/VVx…
RT @tgtxdough: @tgtxdough LR NEURO accompanies approaching LIFE CYCLE inflection points -M&A $ACAD $NBIX $SAGE $GWPH $ALDR https://t.co/VVx…
RT @AndyBiotech: $NBIX FDA Approves Ingrezza for tardive dyskinesia
https://t.co/oYMdv3eDgW
More information about $NBIX on https://t.co/9zNPOm2SL9 #np #inspiration https://t.co/NXq8V5R0r3
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
Recommendation #HOLD for $NBIX with UB rating - 1.74 out of 5. https://t.co/D4M1VwsdbJ
@adamfeuerstein Then $TEVA scoops up $NBIX :)
RT @DrSManian: $NBIX A buyout for this derisked clin stage asset + clean label is virtually certain at this point - expect buyout at a big…
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
$NBIX, we picked it in 10/16 (PT=$70). Check out more such biotech/pharma investments. Free 2-weeks trial
https://t.co/r2JrJpHkU6
Wondering about risks of $NBIX? The 21-day volatility is 11.91% https://t.co/iMoZl9QMae
RT @AndyBiotech: $NBIX Ingrezza label out, no blackbox warning as $TEVA AUSTEDO https://t.co/JStlQTig0z
RT @BioWorld: Ingrezza green-lighted in tardive dyskinesia; $NBIX keeps pricing under wraps https://t.co/65u4fNZXmw
RT @Skipjackrick: $NBIX approved
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
$NBIX float of 88M appears approx 98% institutional (prob sit on news) and 1% insider. Small position.
Unicorn Bay rating for $NBIX is 1.74 out of 5. https://t.co/M4GMXP8zwz
RT @AndyBiotech: $NBIX FDA Approves Ingrezza for tardive dyskinesia
https://t.co/oYMdv3eDgW
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
RT @LTbioinvestor: Sceptical about #biotechs the near term but some quality names look attractive down here :
$nbix $avxs $gbt $clvs $blue…
RT @JohnCendpts: Let's get this Ingrezza approval cleared ASAP, guys. Right?
$NBIX?
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
Thank you $NBIX. Nice labeling outcome also.
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
Pipeline is much broader than just INGREZZA https://t.co/KZilEXGa8F
RT @DrSManian: $NBIX INGREZZA Launch https://t.co/k8rqnVPeeV
RT @DrSManian: $NBIX INGREZZA Launch https://t.co/k8rqnVPeeV
RT @DrSManian: $NBIX
Would not be surprised to see Perceptive & BB Biotech ADD to their large pos here @50 / MC still v low https://t.co/…
RT @DrSManian: .@50 $NBIX HC Wainwright PT 2/17 (pre-approval with clean label) 100$ - I believe a buyout happens by EOY in 100-110$ range…
RT @DrSManian: $NBIX
Would not be surprised to see Perceptive & BB Biotech ADD to their large pos here @50 / MC still v low https://t.co/…
$NBIX INGREZZA Launch https://t.co/k8rqnVPeeV
@jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
@jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
Pipeline is much broader than just INGREZZA https://t.co/KZilEXGa8F
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
RT @jfais20: $NBIX FDA approval INGREZZA first and only for treatment of adults with TD, distribution channel next week and avlbl select ph…
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
Neurocrine Bioscience Receives FDA Approval For Ingrezza For Treatment Of TD; Stock Jumps 19% $NBIX $TEVA https://t.co/iT3LGIeJkM
RT @BioWorld: Ingrezza green-lighted in tardive dyskinesia; $NBIX keeps pricing under wraps https://t.co/65u4fNZXmw
Ingrezza green-lighted in tardive dyskinesia; $NBIX keeps pricing under wraps https://t.co/65u4fNZXmw
RT @AndyBiotech: $NBIX Ingrezza label out, no blackbox warning as $TEVA AUSTEDO https://t.co/JStlQTig0z
RT @tgtxdough: @chillipickle7 Barclays $NBIX start actively promoting on May 1 remains among our preferred midcap names 2017maintain Overw…
RT @tgtxdough: @tgtxdough leerink $NBIX remains a top pic https://t.co/wt6QBIJPA6
@jeffwel1 @Pharmdca @AdamSinger @RGstocktrader @Lblegend33 @DrSManian And Did your dd and research then go ahead an… https://t.co/zVsjhX7k6Z
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
@TheBio_Hunter Nice call on $NBIX. Congrats on the solid play.
Explore #fundamental numbers and pros and cons for $NBIX https://t.co/73gJXzNNQP
RT @jfais20: $NBIX FDA approval INGREZZA first and only for treatment of adults with TD, distribution channel next week and avlbl select ph…
$NBIX socially trending now, check out why at https://t.co/Z4jiPlRyXu #Davosa #Steinway https://t.co/Q5Uz0J01J1
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
RT @tgtxdough: @chillipickle7 Barclays $NBIX start actively promoting on May 1 remains among our preferred midcap names 2017maintain Overw…
@chillipickle7 Barclays $NBIX start actively promoting on May 1 remains among our preferred midcap names 2017maintain Overweight $60 PT.
Trending on #StockTwits $NBIX at https://t.co/SK4fWt09Ys #books #ASMSG
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class effect). Reit $65 PT
$NBIX FDA approved INGREZZA (valbenazine) for Adults with Tardive Dyskinesia https://t.co/WLldkscOx3
RT @DrSManian: .@50 $NBIX HC Wainwright PT 2/17 (pre-approval with clean label) 100$ - I believe a buyout happens by EOY in 100-110$ range…
RT @DrSManian: .@50 $NBIX HC Wainwright PT 2/17 (pre-approval with clean label) 100$ - I believe a buyout happens by EOY in 100-110$ range…
RT @DrSManian: $NBIX
Would not be surprised to see Perceptive & BB Biotech ADD to their large pos here @50 / MC still v low https://t.co/…
RT @JorelLaraKalel: Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug $NBIX $TEVA https://t.co/yK7QSV2jaH @thestreet
RT @DrSManian: .@50 $NBIX HC Wainwright PT 2/17 (pre-approval with clean label) 100$ - I believe a buyout happens by EOY in 100-110$ range…
.@50 $NBIX HC Wainwright PT 2/17 (pre-approval with clean label) 100$ - I believe a buyout happens by EOY in 100-11… https://t.co/K3AwmCNf42
RT @tgtxdough: @tgtxdough leerink $NBIX remains a top pic https://t.co/wt6QBIJPA6
RT @DrSManian: $NBIX 1M Sh a/h vol on a 49$ stock - this isn't retail buying
RT @DrSManian: $NBIX
Would not be surprised to see Perceptive & BB Biotech ADD to their large pos here @50 / MC still v low https://t.co/…
RT @SolarMelt: $NBIX Sick as a dog, but it helps to see this thing came thru. You know what I did ... Lazy Bull.
$NBIX Sick as a dog, but it helps to see this thing came thru. You know what I did ... Lazy Bull.
$NBIX, $NAK, $TSLA, $INNL, $WLB, $RHT, $POTN, $PULM, $ARLZ $DTII, $CATB, $MYSZ, $RNVA - and that sums up my last 30 days of positive plays
$NBIX
Would not be surprised to see Perceptive & BB Biotech ADD to their large pos here @50 / MC still v low https://t.co/JtP5pZaMQr
$NBIX, $NBRV, $ITEK, $TNXP and more...
US Biotech/Pharma Sector Update: April 11 (investing insights)
https://t.co/NQGhqAFygT
RT @stockspotify: $nbix bluehorse said its a deal
RT @DrSManian: $NBIX will be seeing new 52w highs soon. Likely goes a lot higher as buyout chatter gains traction
This is Perceprive no1…
@BioEeks Model worked for $NBIX today. Not getting my hopes up but definitely excited #FdaApproval
RT @LTbioinvestor: Sceptical about #biotechs the near term but some quality names look attractive down here :
$nbix $avxs $gbt $clvs $blue…
RT @tgtxdough: $NBIX INGREZZA PDUFA for Tardive Dyskinesia (TD) is on Tuesday (4/11) $TEVA
RT @ProfitTradeRoom: What's your call for $NADL tomorrow?
RETWEET if you think it goes UP⬆
LIKE if you think it goes DOWN⬇
$PLUG $NBIX $AU…
RT @AndyBiotech: Two FDA approval decisions to watch this week
$NBIX Ingrezza for tardive dyskinesia
$INCY $LLY Olumiant for rheumatoid a…
RT @DrSManian: $NBIX A buyout for this derisked clin stage asset + clean label is virtually certain at this point - expect buyout at a big…
$PTLA similar to $NBIX, no Adcomm implies approval!!!!!!
$NBIX to announce Ingrezza price concurrent with May sales rep rollout
$NBIX: Ingrezza to be priced 'competitively'
$NBIX: Ingrezza label features no boxed warnings or contraindications
$NBIX bags an FDA OK for tardive dyskinesia, setting up a showdown with $TEVA and first commercial launch https://t.co/9DnobQfPER
$NBIX +19.3% announces FDA approval of INGREZZA capsules https://t.co/rE305X3Zru
Why NBIX Is UP In After Hours Trading Neurocrine Biosciences, Inc. https://t.co/vm9NUtcJqQ $NBIX
Aftermarket surge for $NBIX following FDA-approval for the first and only FDA-approved product for adults with TD. $NBIX outlook positive.
RT @bradloncar: $NBIX follows $TSRO, $BIIB, $IONS in the new normal of biotech PR. https://t.co/EUhnmqr81h
RT @stockspastor: $NBIX approved as predicted. Will do more DD on $BMRN and $INCY tonight to see their chances of getting #FDA approval la…
RT @bs2537: $NBIX, $NBRV, $ITEK, $TNXP and more...
US Biotech/Pharma Sector Update: April 11 (investing insights)
https://t.co/NQGhqAFygT
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
RT @chillipickle7: DB: $NBIX view label better than expected w/ no black-box on depression, suicidality (prior assumptions viewed as class…
RT @tgtxdough: @chillipickle7 Barclays $NBIX start actively promoting on May 1 remains among our preferred midcap names 2017maintain Overw…
RT @TalkMarkets: Neurocrine Bioscience Receives FDA Approval For Ingrezza For Treatment Of TD; Stock Jumps 19% $NBIX $TEVA https://t.co/iT3…
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
Pipeline is much broader than just INGREZZA https://t.co/KZilEXGa8F
RT @JohnCendpts: Neurocrine bags an FDA OK for tardive dyskinesia, setting up a showdown with Teva and first commercial launch
$NBIX
https:…
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
RT @biod694: Thank you $NBIX. Nice labeling outcome also.
RT @tickerws: $NBIX +19.3% announces FDA approval of INGREZZA capsules https://t.co/rE305X3Zru
RT @tickerws: $NBIX bags an FDA OK for tardive dyskinesia, setting up a showdown with $TEVA and first commercial launch https://t.co/9DnobQ…
RT @tickerws: $NBIX: Ingrezza label features no boxed warnings or contraindications
RT @tickerws: $NBIX: Ingrezza to be priced 'competitively'
RT @tickerws: $NBIX to announce Ingrezza price concurrent with May sales rep rollout
RT @SvacFinancial: Aftermarket surge for $NBIX following FDA-approval for the first and only FDA-approved product for adults with TD. $NBIX…
RT @ProfitTradeRoom: What's your call for $NADL tomorrow?
RETWEET if you think it goes UP⬆
LIKE if you think it goes DOWN⬇
$PLUG $NBIX $AU…
Ingrezza green-lighted in tardive dyskinesia but no pricing until next month's launch https://t.co/65u4fNImuY $NBIX
RT @AndyBiotech: $NBIX FDA Approves Ingrezza for tardive dyskinesia
https://t.co/oYMdv3eDgW
Ingrezza's unexpected clean label is a big win for $NBIX. Until $TEVA fix its BBlabel, it will continue to lose this battle by a wide margin
FDA OKs @neurocrine1 Biosciences ’s #neurological disorder drug
$NBIX
https://t.co/NHAIa2Bwk0
https://t.co/eFN9yT5p6z // Stock Market Weekly Review $SPY $WDAY $AMBA $NBIX... // $NBIX #trading #investing #stocks https://t.co/ViqtyzrPzl
Sellside consensus for Ingrezza, though still not clear what the pricing will be $NBIX Via @evaluatepharma https://t.co/QjB3ZGIOg1
Why NBIX Is UP In After Hours Trading Neurocrine Biosciences, Inc. https://t.co/vm9NUtukPq $NBIX
Do you know that #Book Value for $NBIX is $3.62 https://t.co/IBhqYxqcVm
RT @stockstreamtv: https://t.co/eFN9yT5p6z // Stock Market Weekly Review $SPY $WDAY $AMBA $NBIX... // $NBIX #trading #investing #stocks htt…
bmo $NBIX Best Case Scenario Plays Out for Ingrezza Label; Visibility for Upside >$100 @_B_I_O_T_E_C_H_ https://t.co/uPhF6rtXO6
bmo $NBIX
Best Case Scenario Plays Out for Ingrezza Label; Visibility for Upside >$100
RT @AndyBiotech: $NBIX Ingrezza label out, no blackbox warning as $TEVA AUSTEDO https://t.co/JStlQTig0z
RT @DrSManian: @jeffwel1 @Pharmdca @skaushi @Lblegend33 $NBIX
TDK market size https://t.co/JqD3OyiiUV
RT @stockstreamtv: https://t.co/eFN9yT5p6z // Stock Market Weekly Review $SPY $WDAY $AMBA $NBIX... // $NBIX #trading #investing #stocks htt…
RT @_B_I_O_T_E_C_H_: bmo $NBIX
Best Case Scenario Plays Out for Ingrezza Label; Visibility for Upside >$1…
$NBIX $51's....wow.
$NBIX price target raised to $65 from $58 at Jefferies
$NBIX Mitsubishi has rights to Japan and some parts of asia https://t.co/WWAj4NmIfQ